- CLINICAL CORE The Mayo ADRC Clinical Core recruits, evaluates and follows longitudinally persons with cognitive disorders as well as cognitively normal persons who serve as controls. The Clinical Core is led by 4 behavioral neurologists (one in Jacksonville and 3 in Rochester) who have considerable expertise in the cognitive syndromes of the Alzheimer's disease (AD) and non-Alzheimer degenerative spectrum, as well as the cerebrovascular spectrum. In the past 4 years, the Mayo ADRC has made significant contributions in the areas of genetics and imaging of AD, the genetics, imaging and clinical characterization of the syndromes of frontotemporal lobar degeneration, and the clinical and imaging characterization of Dementia with Lewy Bodies. We have participated in numerous national consortia for clinical trials (industry and ADCS), genetics (ADGC) and imaging (ADNI). We have had excellent success with recruiting and retaining our research participants. In the past 4 years, we have recruited African American participants into a variety of projects and trials. Moreover, in conjunction with our Outreach, Recruitment and Education Core, we have a great increase in the number of African American participants who have agreed to brain donation after death. Although we do not require autopsy consent from our participants, our overall autopsy rate was 54%. For the new grant cycle, we intend to continue our activities in these focus areas. Thus, our specific aims include recruiting and following persons in the AD degenerative spectrum, persons with Dementia with Lewy Bodies and persons with frontotemporal lobar degeneration (FTLD) spectrum from preclinical to dementia. We will also recruit cognitively normal volunteers who agree to undergo brain imaging and cognitively normal persons with sleep disorders such as REM Sleep Behavior Disorder that are known to be predictive of synucleinopathy. This latter group will be recruited in order to address an understudied area, namely the preclinical manifestations of Lewy Body Disease. Our interest in this unique group of individuals takes advantage of our longstanding involvement in both mild cognitive impairment and in the Lewy Body Disease spectrum. We will also devote the necessary resources and effort for enhancing our recruiting and following of African American normal volunteers and patients with disorders in the AD, DLB and FTLD spectra. In support of another of our aims, we will obtain DNA on cognitively normal, MCI and dementia participants (AD, LBD, FTLD) in order to supply ADRC-related genetics projects with genetic material. All of the persons who are recruited and followed by the Mayo ADRC will have an evaluation by a behavioral neurologist, a neuropsychological assessment battery that includes the UDS as well as additional procedures, and multimodal brain imaging for the majority of participants. The Clinical Core will continue to work closely with the Neuropathology Core and ADRC related projects that require clinical- pathological correlation.

Public Health Relevance

- CLINICAL CORE The Mayo ADRC Clinical Core is the interface between our research enterprise and our patients. Our participants are extraordinarily well-studied, enabling detailed clinical-imaging-pathological correlations. The Clinical Core activities are a test-bed for improving clinical diagnosis of cognitive disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-19
Application #
9259901
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
19
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Allen, Mariet; Wang, Xue; Burgess, Jeremy D et al. (2018) Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimers Dement 14:352-366
Stricker, Nikki H; Lundt, Emily S; Edwards, Kelly K et al. (2018) Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: assessing cross-modality equivalence of computerized neuropsychological tests. Clin Neuropsychol :1-25
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Bove, Riley M; Patrick, Ellis; Aubin, Cristin McCabe et al. (2018) Reproductive period and epigenetic modifications of the oxidative phosphorylation pathway in the human prefrontal cortex. PLoS One 13:e0199073
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Sun, Wenyan; Samimi, Hanie; Gamez, Maria et al. (2018) Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat Neurosci 21:1038-1048
Zhao, Na; Liu, Chia-Chen; Qiao, Wenhui et al. (2018) Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry 83:347-357
Graff-Radford, Jonathan; Rabinstein, Alejandro A; Lesnick, Timothy G et al. (2018) Microinfarcts and blood pressure trajectories: response to Dr Niu et al. J Hum Hypertens 32:385

Showing the most recent 10 out of 1014 publications